Abhiram S Rao1, Daniel Lindholm2,3, Manuel A Rivas4, Joshua W Knowles5, Stephen B Montgomery6,7, Erik Ingelsson8,5. 1. Department of Bioengineering (A.S.R.). 2. Stanford University School of Medicine, CA. Division of Cardiology, Department of Medical Sciences (D.L.). 3. Uppsala University, Sweden. Uppsala Clinical Research Center, Uppsala, Sweden (D.L.). 4. Stanford University, CA. Department of Biomedical Data Science (M.A.R.). 5. Division of Cardiology, Department of Medicine (J.W.K., E.I.). 6. Department of Genetics (S.B.M.). 7. Department of Pathology (S.B.M.). 8. Stanford Cardiovascular Institute (E.I.) eriking@stanford.edu.
Abstract
BACKGROUND: PCSK9 inhibition is a potent new therapy for hypercholesterolemia and cardiovascular disease. Although short-term clinical trial results have not demonstrated major adverse effects, long-term data will not be available for some time. Genetic studies in large biobanks offer a unique opportunity to predict drug effects and provide context for the evaluation of future clinical trial outcomes. METHODS: We tested the association of the PCSK9 missense variant rs11591147 with predefined phenotypes and phenome-wide, in 337 536 individuals of British ancestry in the UK Biobank, with independent discovery and replication. Using a Bayesian statistical method, we leveraged phenotype correlations to evaluate the phenome-wide impact of PCSK9 inhibition with higher power at a finer resolution. RESULTS: The T allele of rs11591147 showed a protective effect on hyperlipidemia (odds ratio, 0.63±0.04; P=2.32×10-38), coronary heart disease (odds ratio, 0.73±0.09; P=1.05×10-6), and ischemic stroke (odds ratio, 0.61±0.18; P=2.40×10-3) and was associated with increased type 2 diabetes mellitus risk adjusted for lipid-lowering medication status (odds ratio, 1.24±0.10; P=1.98×10-7). We did not observe associations with cataracts, heart failure, atrial fibrillation, and cognitive dysfunction. Leveraging phenotype correlations, we observed evidence of a protective association with cerebral infarction and vascular occlusion. These results explore the effects of direct PCSK9 inhibition; off-target effects cannot be predicted using this approach. CONCLUSIONS: This result represents the first genetic evidence in a large cohort for the protective effect of PCSK9 inhibition on ischemic stroke and corroborates exploratory evidence from clinical trials. PCSK9 inhibition was not associated with variables other than those related to LDL (low-density lipoprotein) cholesterol, atherosclerosis, and type 2 diabetes mellitus, suggesting that other effects are either small or absent.
BACKGROUND: PCSK9 inhibition is a potent new therapy for hypercholesterolemia and cardiovascular disease. Although short-term clinical trial results have not demonstrated major adverse effects, long-term data will not be available for some time. Genetic studies in large biobanks offer a unique opportunity to predict drug effects and provide context for the evaluation of future clinical trial outcomes. METHODS: We tested the association of the PCSK9 missense variant rs11591147 with predefined phenotypes and phenome-wide, in 337 536 individuals of British ancestry in the UK Biobank, with independent discovery and replication. Using a Bayesian statistical method, we leveraged phenotype correlations to evaluate the phenome-wide impact of PCSK9 inhibition with higher power at a finer resolution. RESULTS: The T allele of rs11591147 showed a protective effect on hyperlipidemia (odds ratio, 0.63±0.04; P=2.32×10-38), coronary heart disease (odds ratio, 0.73±0.09; P=1.05×10-6), and ischemic stroke (odds ratio, 0.61±0.18; P=2.40×10-3) and was associated with increased type 2 diabetes mellitus risk adjusted for lipid-lowering medication status (odds ratio, 1.24±0.10; P=1.98×10-7). We did not observe associations with cataracts, heart failure, atrial fibrillation, and cognitive dysfunction. Leveraging phenotype correlations, we observed evidence of a protective association with cerebral infarction and vascular occlusion. These results explore the effects of direct PCSK9 inhibition; off-target effects cannot be predicted using this approach. CONCLUSIONS: This result represents the first genetic evidence in a large cohort for the protective effect of PCSK9 inhibition on ischemic stroke and corroborates exploratory evidence from clinical trials. PCSK9 inhibition was not associated with variables other than those related to LDL (low-density lipoprotein) cholesterol, atherosclerosis, and type 2 diabetes mellitus, suggesting that other effects are either small or absent.
Authors: Brian A Ference; Jennifer G Robinson; Robert D Brook; Alberico L Catapano; M John Chapman; David R Neff; Szilard Voros; Robert P Giugliano; George Davey Smith; Sergio Fazio; Marc S Sabatine Journal: N Engl J Med Date: 2016-12-01 Impact factor: 91.245
Authors: Wei Gan; Robert J Clarke; Anubha Mahajan; Benard Kulohoma; Hidetoshi Kitajima; Neil R Robertson; N William Rayner; Robin G Walters; Michael V Holmes; Zhengming Chen; Mark I McCarthy Journal: Wellcome Open Res Date: 2017-08-22
Authors: Michael Wainberg; Andrew T Magis; John C Earls; Jennifer C Lovejoy; Nasa Sinnott-Armstrong; Gilbert S Omenn; Leroy Hood; Nathan D Price Journal: Proc Natl Acad Sci U S A Date: 2020-08-19 Impact factor: 11.205
Authors: Keren J Carss; Aimee M Deaton; Alberto Del Rio-Espinola; Dorothée Diogo; Mark Fielden; Diptee A Kulkarni; Jonathan Moggs; Peter Newham; Matthew R Nelson; Frank D Sistare; Lucas D Ward; Jing Yuan Journal: Nat Rev Drug Discov Date: 2022-10-19 Impact factor: 112.288
Authors: Kiran Musunuru; Alexandra C Chadwick; Taiji Mizoguchi; Sara P Garcia; Jamie E DeNizio; Caroline W Reiss; Kui Wang; Sowmya Iyer; Chaitali Dutta; Victoria Clendaniel; Michael Amaonye; Aaron Beach; Kathleen Berth; Souvik Biswas; Maurine C Braun; Huei-Mei Chen; Thomas V Colace; John D Ganey; Soumyashree A Gangopadhyay; Ryan Garrity; Lisa N Kasiewicz; Jennifer Lavoie; James A Madsen; Yuri Matsumoto; Anne Marie Mazzola; Yusuf S Nasrullah; Joseph Nneji; Huilan Ren; Athul Sanjeev; Madeleine Shay; Mary R Stahley; Steven H Y Fan; Ying K Tam; Nicole M Gaudelli; Giuseppe Ciaramella; Leslie E Stolz; Padma Malyala; Christopher J Cheng; Kallanthottathil G Rajeev; Ellen Rohde; Andrew M Bellinger; Sekar Kathiresan Journal: Nature Date: 2021-05-19 Impact factor: 69.504
Authors: Maya S Safarova; Benjamin A Satterfield; Xiao Fan; Erin E Austin; Zhan Ye; Lisa Bastarache; Neil Zheng; Marylyn D Ritchie; Kenneth M Borthwick; Marc S Williams; Eric B Larson; Aaron Scrol; Gail P Jarvik; David R Crosslin; Kathleen Leppig; Laura J Rasmussen-Torvik; Sarah A Pendergrass; Amy C Sturm; Bahram Namjou; Amy Sanghavi Shah; Robert J Carroll; Wendy K Chung; Wei-Qi Wei; QiPing Feng; C Michael Stein; Dan M Roden; Teri A Manolio; Daniel J Schaid; Joshua C Denny; Scott J Hebbring; Mariza de Andrade; Iftikhar J Kullo Journal: NPJ Genom Med Date: 2019-02-11 Impact factor: 8.617
Authors: Nicolas Perrot; Vincenza Valerio; Donato Moschetta; S Matthijs Boekholdt; Christian Dina; Hao Yu Chen; Erik Abner; Andreas Martinsson; Hasanga D Manikpurage; Sidwell Rigade; Romain Capoulade; Elvira Mass; Marie-Annick Clavel; Thierry Le Tourneau; David Messika-Zeitoun; Nicholas J Wareham; James C Engert; Gianluca Polvani; Philippe Pibarot; Tõnu Esko; J Gustav Smith; Patrick Mathieu; George Thanassoulis; Jean-Jacques Schott; Yohan Bossé; Marina Camera; Sébastien Thériault; Paolo Poggio; Benoit J Arsenault Journal: JACC Basic Transl Sci Date: 2020-07-01